Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy entities : Fate therapeutics, inc. save search
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
| Email alert
Add to watchlist
meeting t-cell therapeutics therapy
629AB, Associate Director / Principal Scientist, Flow Cytometry Cell Therapy Analytics
Published: 2021-12-24 (Crawled : 01:00) - fatetherapeutics.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
| Email alert
Add to watchlist
analytics cel therapy
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
ft516 fda granted therapeutics phase 1 positive therapy t-cell designation
599CC, Senior Scientist, Cancer Immunotherapy (T cell enhancement)
Published: 2021-10-08 (Crawled : 18:00) - fatetherapeutics.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
| Email alert
Add to watchlist
immunotherapy therapy cancer t-cell
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
Published: 2021-10-01 (Crawled : 12:15) - globenewswire.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: 0.66%
H: 1.36%
C: -0.27%
presentation immunotherapy therapy cancer
508BG, Senior Scientist / Scientist, Cancer Immunotherapy (Solid Tumor)
Published: 2021-09-21 (Crawled : 17:00) - fatetherapeutics.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: 0.71%
H: 4.82%
C: 0.66%
immunotherapy therapy cancer solid tumors
588AS, Scientist / Associate Scientist, Cancer Immunotherapy
Published: 2021-09-21 (Crawled : 17:00) - fatetherapeutics.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: 0.71%
H: 4.82%
C: 0.66%
immunotherapy therapy cancer
559SL, Scientist / Associate Scientist, Cancer Immunotherapy (Differentiation & Hematopoiesis)
Published: 2021-08-20 (Crawled : 17:00) - fatetherapeutics.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: -15.2%
H: 0.54%
C: -7.71%
immunotherapy therapy cancer
Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy
Published: 2021-08-02 (Crawled : 21:00) - globenewswire.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: -3.32%
treatment phase 1 therapy trial t-cell car-t
533MH, Scientist, Cancer Immunotherapy
Published: 2021-07-02 (Crawled : 19:00) - fatetherapeutics.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
| Email alert
Add to watchlist
immunotherapy therapy cancer
Worldwide CAR-T Cell Therapy Industry - Featuring Aleta BioTherapeutics, Atara Biotherapeutics and BioNTech Among Others
Published: 2021-06-04 (Crawled : 16:00) - prnewswire.com
BMY | $48.86 -0.27% 0.0% 16M
|
Health Technology
|
| O: 0.28%
H: 0.38%
C: -0.06%
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 1.73%
H: 2.43%
C: -1.58%
PGEN | $1.42 1.43% 1.41% 560K
|
Health Technology
|
| O: 1.07%
H: 3.01%
C: 0.45%
PSTX | $2.065 -4.4% -4.6% 350K
|
Health Technology
|
| O: -1.07%
H: 2.53%
C: 0.84%
MBIO | $0.35 -2.7% -2.77% 120K
|
Health Technology
|
| O: 2.46%
H: 8.41%
C: 6.91%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.47%
H: 1.17%
C: 0.96%
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: 1.53%
H: 9.81%
C: 6.61%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 0.0%
H: 2.74%
C: 0.68%
ANIX | $3.1 0.98% 0.97% 360K
|
Health Technology
|
| O: 1.78%
H: 6.25%
C: 3.0%
therapy car-t iot t-cell
508BG, Senior Scientist / Scientist, Cancer Immunotherapy (Solid Tumor)
Published: 2021-04-23 (Crawled : 23:00) - fatetherapeutics.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
| Email alert
Add to watchlist
immunotherapy therapy cancer solid tumors
510BY, Associate Scientist / Senior Research Associate, Cancer Immunotherapy
Published: 2021-04-23 (Crawled : 23:00) - fatetherapeutics.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
| Email alert
Add to watchlist
immunotherapy therapy cancer research
500GH, Senior Research Associate / Research Associate, Cancer Immunotherapy
Published: 2021-04-12 (Crawled : 00:00) - fatetherapeutics.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: 0.01%
H: 6.6%
C: 5.19%
immunotherapy therapy cancer research
484MH, Senior Scientist / Scientist, Cancer Immunotherapy
Published: 2021-03-25 (Crawled : 01:00) - fatetherapeutics.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: -6.07%
H: 2.81%
C: 1.97%
immunotherapy therapy cancer
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.